In vitro antibacterial activities of a novel oxazolidinone, OCID0050.
OBJECTIVE
In the pursuit of developing a second-generation oxazolidinone, we have identified OCID0050 as a novel oxazolidinone with enhanced activity against bacterial strains resistant to methicillin, vancomycin and linezolid.


METHODS
MIC and MBC determinations were performed according to CLSI guidelines. Linezolid-resistant bacterial strains were generated in-house; inoculum effect, pH effect and kill kinetics experiments were performed as per standard protocols.


CONCLUSIONS
OCID0050 demonstrated better inhibitory potency against many of the tested clinically significant strains by generally showing 2-4-fold lower MICs than linezolid. In addition, it has higher inhibitory activity against linezolid-resistant strains.
Paul-Satyaseela
Maneesh
M
Anti-infectives Discovery, Department of Microbiology, Orchid Research Laboratories Ltd, 476/14, OMR, Sholinganallur, Chennai 600 119 (TN), India. ipm@orchidpharma.com
Solanki
Shakti Singh
SS
Sathishkumar
Devarajan
D
Bharani
Thirunavukkarasu
T
Magesh
Vijayan
V
Rajagopal
Sriram
S
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D050296:Microbial Viability / Q000187:drug effects; D023303:Oxazolidinones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; C545472:OCID0050; D023303:Oxazolidinones